55 results about "Choleretic" patented technology

The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and/or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).

The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, M1, M2, m, n, Q, L, ring A, ring B and ring C are as defined in the specification. The invention further relates to a preparation method of the compounds, and application in preparing medicines for treating and/or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication and malignant tumors mediated by an FXR. The formula (I) is shown in the description.

The invention discloses a Chinese medicine composition for treating an autoimmune liver disease. The Chinese medicine composition is prepared from the Chinese medicinal materials, namely rheum officinale, radix rubiae, fructus forsythia, herba siegesbeckiae, large-leaved gentian and liquorice. The invention also discloses a preparation method of the Chinese medicine composition and application of the Chinese medicine composition. The composition has the effects of clearing away heat and toxic materials, smoothing liver-gallbladder, and promoting blood circulation to remove blood stasis, and is mainly used for treating autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.

The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, R4, W, A, Z, E, X, Y and n are as defined in the specification and the claims. The invention further relates to a preparation method of the compounds, pharmaceutical preparation and application in preparing medicines for treating and/or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication andmalignant tumors mediated by an FXR. The formula (I) is shown in the description.

The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(tri-fluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC). In some embodiments, the methods further comprise administering Compound 1, or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement. Other embodiments, relate to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC).

The invention relates to an application of an encoding gene ESRRA of an estrogen-related receptor alpha (ERR alpha) in preparation of a medicine for preventing or treating liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The adeno-associated virus is utilized to construct an ERRalpha overexpression vector system, and the fact that the ERR alpha gene and a delivery system of the ERR alpha gene can be used for preventing or treating the liver diseases is proved on various disease models.

The invention relates to a traditional Chinese medicinal composition for treating primary biliary cirrhosis and a preparation method thereof. The traditional Chinese medicinal composition can be used for effectively solving the problems of poor and unstable curative effect, toxic and side effects and easy recurrence and is prepared from the following raw materials in parts by weight: 500-1500 parts of bupleurum, 300-800 parts of chinaroot greenbrier, 500-1500 parts of radix ranunculi ternati, 1000-2000 parts of madder, 300-500 parts of leech, 500-1000 parts of earthworm and 500-1500 parts of liquorice. The traditional Chinese medicinal composition provided by the invention has the main effects of clearing away heat and toxic materials, soothing the liver and gallbladder and promoting blood circulation to remove blood stasis, is good at treating the primary biliary cirrhosis with liver and gallbladder stasis, dampness-heat stay inside and qi stagnation and blood stasis syndromes, adopts liver and gallbladder soothing, blood circulation promoting and blood stasis removing as main therapies, integrates pharmaceutical effects of soothing gallbladder, promoting menstruational flow and regulating flow of qi and combined action of main and collateral channels into a whole and has high significant efficiency and effective rate, stable curative effect, no recurrence, small side effect and low cost.

The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg/day and/or spironolactone >100 mg/day or equivalent doses of an alternative loop-acting and/or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

The invention discloses a molecular marker for diagnosing primary biliary cholangitis and application thereof. According to the present invention, the anti-human multimer immunoglobulin receptor antibody is adopted as the primary biliary cholangitis diagnosis molecular marker so as to prepare the diagnosis reagent; the human multimer immunoglobulin receptor antibody is remarkably increased in serum of PBC AMA-M2 subtype positive and negative patients, which indicates that in the attack of PBC, the serum anti-human multimer immunoglobulin receptor antibody specifically targets human multimer immunoglobulin receptors on small and medium bile ducts in the liver, thereby causing damage to the small and medium bile ducts. According to the invention, a new explanation is provided for the pathogenesis of the PBC, and in addition, a new means is provided for the specific diagnosis of the PBC by detecting the level of the serum anti-human multimeric immune globulin receptor antibody. The method is simple and reliable, materials are convenient to obtain, and the method has great application value in PBC diagnosis.

The invention provides choleretic Chinese patent medicine which is prepared from radix curcumae, endothelium corneum gigeriae galli, aloe, black alum, potassium nitrate and fresh pig's bile. The choleretic Chinese patent medicine is quick in action, good in treatment effect, less prone to causing recurrence and convenient to eat, operational risk is avoided, the preparation process is simple, and the choleretic Chinese patent medicine is suitable for mass production and wide popularization.

The invention discloses a directional separation method for immune adjustment intestinal lactobacillus, and belongs to the technical field of biological preparations. A biotinylated IgA antibody is used for treating animal or human saliva, intestinal contents or fecal bacterial suspension, streptavidin magnetic nano-beads are used for separation, and enrichment culture and selective separation are performed to obtain the intestinal lactobacillus with an immune adjustment function. Compared with a traditional method, the method can rapidly and directionally separate immune adjustment beneficial bacteria, and obtained strains can be used for feed, common food or functional food after acid resistance, bile resistance and adhesion of the strains are further verified.

An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.

The invention discloses application of polypeptide AT03 in a medicine used for treating primary biliary cholangitis. The amino acid sequence of the polypeptide AT03 is Val-His-Val-Val-R1, wherein R1 is -NH2. A large number of experimental studies prove that the polypeptide AT03 has a treatment effect on a common bile duct-ligated rat cholestatic liver cirrhosis model, and the treatment effect is specifically shown in that liver cholestasis, intrahepatic biliary obstruction, liver cell injury and liver tissue fibrosis process can be improved; and the polypeptide AT03 can be used for preparing the medicine used for treating primary biliary cholangitis.

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), characterized by high enzymolysis stability, high biological activity and no adverse reaction. The polypeptide compounds are able to significantly improve a degree of BDL-induced cholestasis hepatic fibrosis in rats, and have significant therapeutic effects on diseases such as biliary cirrhosis. The dual target agonist polypeptides are applicable to the prevention or treatment of biliary cirrhosis and related hepatic fibrosis diseases.

The invention discloses Yinchen Lidan granules, comprising the following components in parts by weight: 5-15 parts by weight of Yin Chen, 1-10 parts by weight of S. 6 parts by weight, 5-15 parts by weight of Daqingye, 1-10 parts by weight of Turmeric, 2-6 parts by weight of Atractylodes Rhizoma, 2-6 parts by weight of Poria, 2-6 parts by weight of Bupleurum, 3-11 parts by weight of Salvia; The preparation for the differentiation and treatment of cholestatic hepatitis is economical and convenient to take, and can shorten the course of disease, improve the curative effect, and fully develop green medical treatment.